Slides
Page 1
© 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 January 2026 Invivyd Corporate Deck
Page 2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “seek,” “could,” “intend,” “target,” “aim,” “project,” “designed to,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, expectations regarding Invivyd’s efforts to develop potential best-in-class antibody therapies across multiple viral threats; expectations about the COVID landscape; beliefs about limitations of COVID vaccines and the expected advantages of monoclonal antibodies (mAbs); expectations regarding durability and stability of the company’s antibodies; plans related to the company’s research and development activities, and the timing and potential results thereof; the potential of VYD2311 as a mAb candidate; expectations regarding the company’s clinical trial designs and enrollment, regulatory pathway, product profile, target patient population, indication and administration paradigm for VYD2311; PEMGARDA® (pemivibart) as a mAb for pre-exposure prophylaxis (PrEP) of COVID-19 in certain immunocompromised persons; the company’s commercialization plans, strategies, goals and expectations; the potential of VBY329 as a novel, potential best-in-class respiratory syncytial virus (RSV) mAb candidate; estimates regarding the size of target patient populations and the potential market opportunity for the company’s product candidates, as well as its market position; the potential of Invivyd’s technology to address major needs beyond COVID; the potential of the company’s pipeline and discovery efforts, including for COVID, Long COVID, RSV and measles; the anticipated focus and goals of the SPEAR Study Group; the company’s business strategies and objectives, and ability to execute on them; the company’s future prospects; the company’s preliminary fourth quarter financial results; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: uncertainties about the company’s expectations, projections and estimates regarding future costs and expenses, future revenue, capital requirements, and the availability of and the need for additional financing; whether the company’s cash and cash equivalents are sufficient to support its operating plan for as long as anticipated; uncertainties regarding market acceptance, payor coverage and reimbursement, or future revenue generated by any authorized or approved product; the timing, progress and results of the company’s discovery, preclinical and clinical development activities; clinical trial site activation or enrollment rates; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity in nonclinical studies; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; how long the emergency use authorization (EUA) granted by the U.S. Food & Drug Administration (FDA) for PEMGARDA for COVID-19 PrEP in certain immunocompromised persons will remain in effect and whether such EUA is revised or revoked by the FDA; changes in the regulatory environment; the outcome of the company’s engagement with regulators; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; whether or not any preclinical candidate identified by the company is determined to be suitable for clinical development; the company’s ability to generate the data needed to support a potential Biologics License Application (BLA) submission for VYD2311; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; the success of the company’s in-house sales force, and company’s ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize any authorized or approved product; changes in expected or existing competition; the company’s reliance on third parties; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitopes that pemivibart and VYD2311 target remain structurally intact and the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the complexities of manufacturing mAb therapies, and availability of quantities of commercial launch product in the future, if authorized or approved; macroeconomic and political uncertainties; any change in the preliminary estimates of the company’s Q4 2025 results upon completion of the company’s financial closing controls and procedures, and finalization of the financial statements; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This presentation contains hyperlinks to information that is not deemed to be incorporated by reference in this presentation. All trademarks used in this presentation are the property of their respective owners. 2
Page 3
agenda 01 Invivyd Approach 02 COVID 03 Long COVID 04 RSV 05 Financial Highlights 3
Page 4
The need is urgent. The market potential is significant. We’re taking action. COVID RSVLONG COVID MEASLES We’re developing potential best- in-class antibody therapies across multiple viral threats, providing protection and defining what’s next in keeping people well. With a broad pipeline and sharp execution, we’re moving quickly to turn breakthrough science into lasting impact and value. 4
Page 5
A Bespoke Platform For ID mAb Discovery 5 Mutable Targets Best-in-Class mAbs Discovery Platform Proprietary Analytics
Page 6
The Right Technology Designed to Address Major Needs Beyond COVID 6 Short Half-Life / Treatment of Infectious Disease Long Half-Life / Prevention of Disease / Vaccine Alternatives COVID RSV Measles Tick-borne (Lyme, etc.)* Pediatric Bridge to Immunologic Maturity (Mumps, Rubella, Diptheria, Pertussis)* COVID RSV Measles Hepatitis B/Delta* Pertussis* * Research Phase
Page 7
agenda 01 Invivyd Approach 02 COVID 03 Long COVID 04 RSV 05 Financial Highlights 7
Page 8
Perceived as a “respiratory” virus because of transmission, but actually a vascular, prothrombotic, immunomodulatory novel virus Influenza Entry via sialic acid receptor Largely bronchoepithelial cells RSV Entry via CX3CR1 Largely bronchoepithelial cells SARS-CoV-2 Entry via ACE2 Epithelial and endothelial cells 8
Page 9
COVID’s systemic complications continue to unfold 9 All trademarks and logos displayed are the property of their respective owners. Their use here is for identification purposes only and does not constitute endorsement or affiliation.
Page 10
10 Only 12.9% of Americans say the main reason they have avoided getting a COVID vaccine in the ‘24 season was because they weren’t worried about getting infected. Source: Centers for Disease Control and Prevention, Reasons for non-vaccination with COVID-19, influenza, and RSV vaccines during the 2023–24 respiratory virus season, November 8, 2024.
Page 11
0.00% 5.00% 10.00% 15.00% 20.00% 25.00% A national CDC survey of adults during June – July 2024 found that when asked to select all reasons that apply, the most common reasons for non -vaccination during the 2023 – 24 respiratory virus season were concerns about serious and unknown side effects for COVID-19 vaccine (39.7%) and lack of concern about getting sick for flu vaccine (36.8 %) among adults aged ≥ 18 years, and lack of knowledge for RSV vaccine (36.1%) among adults aged ≥ 60 years. When asked to select all reasons for not getting a COVID vaccine that apply, 33.6% of Americans say they are not concerned ab out getting sick. COVID Vaccine Source: Centers for Disease Control and Prevention, Reasons for non-vaccination with COVID-19, influenza, and RSV vaccines during the 2023–24 respiratory virus season, November 8, 2024. The current solution is the problem Concerned about serious/ unknown side effects Not concerned about getting infected Choose not to get any vaccine No time/ did not get around to it Don’t trust government 6.7% 8.8% 10.0% 12.9% 20.0% 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% FLU Vaccine Not concerned about getting infected Choose not to get any vaccine No time/did not get around to it Vaccine can’t prevent infection Other 5.7% 5.8% 10.7% 15.5% 20.1% When asked to select all reasons for not getting a COVID or FLU vaccine, respectively, respondents noted the main reason for not getting vaccinated as follows: 11
Page 12
Current Disconnected state of COVID mRNA vaccine prevention 12 Sources: (1) Vaccines and Related Biological Products Advisory Committee Briefing Documents, December 10, 2020. (2) Prescribing Information – COMIRNATY® Aug 2025; Prescribing Information - SPIKEVAX® Aug 2025 (3) New England Journal of Medicine, An Evidence-Based Approach to Covid-19 Vaccination, Vinay Prasad, M.D., M.P.H., and Martin A. Makary, M.D., M.P.H., May 20, 2025. The Clinical Data Phase 3 RCTs: ~2 months of efficacy follow-up Observed Utilization Annual booster The FDA Labels “Once – OR – More than 2 months since last boost dose”
Page 13
In contrast to vaccines, monoclonal antibodies can be engineered for consistent high activity COVID demands monoclonal antibodies 13 13
Page 14
We innovate to stay ahead and seek to improve performance Humans have limited antibody diversity and capability. Invivyd innovation has no such limit. pemivibart VYD2311 Minimally evolved molecular engineered [MEME] 14
Page 15
Engineered against stable epitopes – beyond human immune capability We have seen robust durability and stability of our antibodies 15
Page 16
PEMGARDA is helping establish Invivyd’s long-term commercial foundation Established Strong Commercial Foundation Building from Specialty Infusion Team – Scaling to serve broad market for VYD2311, if approved Developed Focus Messaging to build from – VYD2311 requires a greater presence Access Strategy Shift to serve much larger opportunity In-line commercial team and infrastructure to support long-term growth Accounts w/ PEMGARDA Infusion Experience926 $17.2M* PEMGARDA field force sized to meet the market at centers of excellence Expanding digital presence to reach more HCP specialties Available Sites Infusing Reordering Accounts 77% *Preliminary, unaudited and subject to change; as of December 31, 2025 Conferences/Exhibits Attended125+ GPO Contracted Sites15,500+ 1250+ Expand PEMGARDA market access position for VYD2311 Expanding commercial team to increase reach into broader HCP audiences Establish scalable foundation for mass consumer market Preliminary PEMGARDA Net Product Revenue Q4 ’25 >96% of medical claims in 2025 successfully processed Continued sales growth QoQ in 2025 16 All metrics are Launch to Date (LTD 12/31/25)
Page 17
Broad recognition from Societies and Guidelines for Antibodies in COVID SOCIETY / GUIDELINE PEMGARDA OR MAB TARGET AUDIENCE HIV.gov PEMGARDA Immunodeficiency IDSA Pemivibart Infectious disease NCCN – B-Cell Lymphomas Pemivibart Oncology NCCN – Infection Prevention Pemivibart Oncology Immune Deficiency Foundation (IDF) PEMGARDA Immunodeficiency MS Society PEMGARDA Rheumatology National Kidney Foundation PEMGARDA Solid organ transplant American Cancer Society PEMGARDA Oncology American College of Rheumatology mAbs Rheumatology American Lung Association Pemivibart Oncology National Council on Aging (NCOA) PEMGARDA Elderly BreastCancer.org PEMGARDA Oncology CLL Society PEMGARDA Oncology American Academy of Allergy, Asthma, and Immunology (AAAAI) PEMGARDA Immunology Vasculitis Foundation PEMGARDA Rheumatology Invivyd poised to deliver on scalable form factor for broad access 17
Page 18
$3.8B FY24 U.S. Revenue 18 and over vaccine efficacy (VE) reduction in hospitalization estimate from CDC 2023–2024 vaccine dose, ≥7 days 36% 7–59 days earlier 51% (45–56) 60–119 days earlier 42% (35–48) 120–179 days earlier 15% (3–26) COVID Vaccines: Big Revenue, Small Protection 18 Source: Moderna, Pfizer, and Novavax FY2024 10-Q and 10-K filings. Source: FDA. Effectiveness of COVID-19 (2023-2024 Formula) vaccines, presented to the Advisory Committee on Immunization Practices (ACIP), October 2024. Slide 16. Accessed November 16, 2025
Page 19
Current market offers tailwinds for VYD2311 1 2 3 4 5 mRNA risk/benefit concerns1 Unique non-vaccine MOA with potential to prevent COVID provides a competitive and compelling differentiator Significant unmet need for vaccine alternatives Total addressable market is significant 2 Growing identification of long-term effects of COVID infections3 19Sources: (1) Centers for Disease Control and Prevention (CDC). Reasons for non-vaccination with COVID-19, influenza, and RSV vaccines during the 2023-24 respiratory virus season. RespVaxView. November 8, 2024, (2) Moderna, Pfizer, and Novavax FY2024 10-Q and 10-K filings, (3) University of Nebraska Medical Center. (2025, October 22). Long COVID linked to development of cardiovascular disease. The Transmission.
Page 20
Scale existing commercial efforts for VYD2311, anticipated to be accessible to a broad population 1 2 3 4 5 Expansion of sales force Deepen presence across multiple digital channels 20 Strategies and Tactics designed to increase Awareness, Education, and Activation* *If approved for use by the U.S. FDA, and in accordance with the Prescribing Information Education of healthcare providers beyond specialty medicine, with focus to include primary care Enhance equitable access through evolving patient support programs and expanded market access team Move toward more vaccine-like distribution and partnerships
Page 21
VYD2311/REVOLUTION Clinical Program Phase 1/2 Study Randomized, double-blind, placebo- controlled trial was conducted to evaluate safety, tolerability, pharmacokinetics, and immunogenicity in healthy participants Pivotal Efficacy Study ‘DECLARATION’ Phase 3, placebo-controlled efficacy trial in prevention of symptomatic COVID Vaccine Study ‘LIBERTY’ Safety/Tolerability comparison with COVID mRNA vaccines (and co- administration) 21
Page 22
Screening (up to Day -14) Monitor for CLI symptoms: Day 1 to Day 90 If qualifying CLI symptoms: Confirm in-person with SARS-CoV-2 RT-PCR within 2 days If confirmed COVID: 28-day follow-up *Day 8 and Day 68 PK for ≈ 200 participants at select sites VYD2311 Placebo Placebo R 1:1:1 N1770 VYD2311-SD (single dose) VYD2311-MD (multidose) Placebo VYD2311 VYD2311 VYD2311 Placebo Placebo Placebo 60-Day Treatment Period 30-Day Follow-up Period Day 1 Day 90 End of StudyDay 30 Day 60 Screening (up to Day -14) This study will characterize the safety and tolerability, immunogenicity of COVID vaccines, pharmacokinetics of VYD2311, and neutralizing antibody titers of concomitant administrations of VYD2311 and COVID vaccines, subject to final FDA alignment. R 1:1:1 N~210 VYD2311-SD (single dose) mRNA Vaccine (single dose) Combination VYD2311 and mRNA Vaccine 28-Day Follow-up Period Day 1 End of Study 22
Page 23
Why study VYD2311 in multi-doses? Repeat dose safety and titer data Anticipate that, if approved, most people would choose to get VYD2311 once a year, with a safety profile that enables extra protection for those who want it.* 23 *Depending on Prescribing Information, if approved
Page 24
CP Building a category to serve humanity where they are today Belief that COVID needs to be avoided Trust in Safety and Efficacy Easy access and availability Broad awareness ACIP and Societies’ endorsements Media endorsement Social Media endorsement Consumers Belief that COVID needs to be avoided Trust in Efficacy and Safety Easy access and availability ACIP and Societies’ endorsements HCPs COVID mAbs: potential for equitable, instant, high, safe, natural, vaccine-free protection* Medical/social/political environment potentially primed for disruption of COVID vaccine time to go BIG 24 *If approved for use by the U.S. FDA, and in accordance with the Prescribing Information
Page 25
agenda 01 Invivyd Approach 02 COVID 03 Long COVID 04 RSV 05 Financial Highlights 25
Page 26
SPEAR Group Invivyd and leading researchers have formed the SPEAR (Spike Protein Elimination and Recovery) Study Group to assess the effects of mAb therapy for Long COVID and COVID- 19 Post-Vaccination Syndrome. Key elements of a proposed clinical study to evaluate the effects of mAb therapy on Long COVID were presented in September 2025 on behalf of the SPEAR Study Group to RECOVER-TLC, an NIH initiative devoted to testing potential treatments for Long COVID: 1) Deploying high levels of neutralizing monoclonal antibody over the long -term (months) that confer antiviral activity at or above levels associated with successful treatment of active COVID-19 infection 2) Randomized, placebo-controlled study with more than 100 patients per arm, powered to generate definitive, reliable evidence 3) Enrollment based on biomarkers indicating persistent spike antigen in serum and/or viral RNA in tissue 4) Measuring reduction in detectable spike antigen in serum and/or viral RNA as the critical translational endpoint 5) Exploring potential symptom improvement using standardized instruments to correlate potential modification of potential underlying chronic infection or presence of antigens to clinical benefit 26
Page 27
agenda 01 Invivyd Approach 02 COVID 03 Long COVID 04 RSV 05 Financial Highlights 27
Page 28
Potential best-in-class RSV antibody candidate 28 Pediatric RSV prophylaxis is a blockbuster market expected to grow to $3-$4B in annual revenues globally by 2030. VBY329 is designed for the prevention of RSV infections in newborns, infants, and children and for higher potency and improved barrier to resistance compared to standard of care RSV medicines, as assessed in vitro: Antiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains representing circulating variants Resistance profile compared to nirsevimab reflects up to approximately 500-fold greater enhanced neutralization activity against RSV F protein variants resistant to nirsevimab in pseudovirus assays that reflect contemporary, circulating, nirsevimab-resistant variants associated with various RSV A & B strains Half-life extension technology and biophysical properties expected to confer equivalent or greater in vivo half-life compared to nirsevimab and clesrovimab Potential beginnings of pediatric bundle with COVID and other potential mAbs
Page 29
agenda 01 Invivyd Approach 02 COVID 03 Long COVID 04 RSV 05 Financial Highlights 29
Page 30
Q1 Q2 Q3 Q4 2024 $0 $2.3M $9.3M $13.8M 2025 $11.3M $11.8M $13.1M $17.2M* Financial Highlights Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million* • 25% growth over Q4 2024 • 31% growth over Q3 2025 Preliminary December 2025 ending cash and cash equivalents of $226.7 million*; secured over $200 million of capital in 2H 2025 PEMGARDA® Net Product Revenue 30 *Preliminary, unaudited and subject to change; as of December 31, 2025
Page 31
Invivyd is leading change and shaping the future 31 Enable shift in American / global infectious disease prevention that any perspective or political view can embrace. Stop debating vaccines, start improving on them. • COVID vaccine-only approach to prevention • Central / paternal public health posture (mandate) • Limitation imposed by human immune systems • mRNA / adjuvanted / pathogen-centric platforms Move away from: • Addressing public health crisis of distrust in American healthcare • Individual choice on accessing instant protection • Supra-physiologic protection • Natural supplemental immune support through mAbs • Massive disruption of the COVID vaccine market* Move toward: *If approved for use by the U.S. FDA, and in accordance with the Prescribing Information